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SocietyOne of the critical challenges in developing structure-modi-
fying/preserving therapies for arthritis, especially for knee
osteoarthritis (OA), is measuring changes in progression
of joint destruction. Radiographic measurement of joint-
space narrowing, which is currently recommended in the
Food and Drug Administration (FDA) and European Agency
for the Evaluation of Medicinal Products (EMEA) guidance
documents as the imaging endpoint for clinical trials of dis-
ease-modifying OA drugs (DMOADs), is recognized to be
an insensitive measure of disease onset, activity, and
progression.
Accordingly, new and more sensitive biomarkers are
needed. Magnetic resonance imaging (MRI) offers consid-
erable promise in this regard. Not only can MRI enable
quantiﬁcation of articular cartilage volume and morphology
with high precision and accuracy, it can also examine other
important articular tissues simultaneously. It thus offers
a unique opportunity to evaluate the knee and other joints
as whole organs. This capability is important because OA
is a joint disease that involves not only articular cartilage
and bone but also synovium, menisci, ligaments, tendons
and muscles. Until the relative roles and interdependencies
of these structures in producing the pain and dysfunction
experienced in OA are fully understood, focusing on only
one or two of these features, as is the current practice, pro-
vides an excessively narrow perspective. A more holistic
view is called for.
‘‘Whole-organ’’ assessment could facilitate DMOAD clin-
ical trials and studies exploring the pathophysiology and
epidemiology of OA in a number of ways. For example,
discriminating different patterns of involvement of articular
tissues in knee OA could point to different potential causes
of the disease and thereby suggest different therapeutic
strategies for speciﬁc patient subgroups. Whole-organ as-
sessment may also potentially uncover preclinical stages
of OA or structural risk factors for developing clinical OA,
as well as increase the sensitivity to change for disease
progression and treatment response. This approach would
aid in subject selection, treatment monitoring and safety
assessment.
However, there are numerous practical and theoretical
challenges associated with whole-organ assessment.
These range from balancing conﬂicting objectives in
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when combining measurements from different structures
or from different regions of the same structure.
In an effort to provide state-of-the-art reviews and recom-
mendations on these and other important considerations
which would offer meaningful guidance to scientists and
pharmaceutical companies designing multi-center clinical
studies of OA, OMERACT (Outcome Measures in Rheuma-
tology Clinical Trials) and OARSI (Osteoarthritis Research
Society International), with support from various pharma-
ceutical companies listed at the beginning of this supple-
ment, held a workshop for Consensus on Osteoarthritis
Imaging in Bethesda, MD, on December 5 and 6, 2002.
The workshop included approximately 150 participants
from the academic, pharmaceutical and regulatory commu-
nities from US, Europe and Australia. Prior to the workshop,
a multidisciplinary, international panel of expert scientists
and physicians met in New Orleans, LA, on October 29,
2002 to deﬁne a preliminary set of MRI features to include
in whole-organ assessment of the knee and to review the
relative strengths and weaknesses of various imaging
protocols for multi-feature, multi-site MRI. To create focus
and utilize available and developing data, only knee imag-
ing was evaluated.
This panel was co-chaired by Charles Peterfy, M.D.,
Ph.D. (Synarc, Inc, San Francisco, CA, USA) and Roy
Altman, M.D. (University of Miami, Miami, FL, USA) and
also included Deborah Burstein, Ph.D. (Harvard-MIT,
Cambridge, MA, USA), Flavia Cicuttini (Epidemiology,
Monash University, Prahran, Australia), Gary Cline, Ph.D.
(Biometrics and Statistical Sciences, Proctor & Gamble
Pharmaceuticals, Madison, OH, USA), Philip Conaghan,
M.B.B.S., F.R.A.C.P. (Rheumatology, Leeds University,
Leeds, UK), Bernard Dardzinski, Ph.D. (MRI Physics, Uni-
versity of Cincinnati, Cincinnati, USA), Felix Eckstein,
M.D. (MR image analysis, Ludwig-Maximilians-Universita¨t,
Mu¨nchen, Germanyb), David Felson, M.D., M.P.H. (Rheu-
matology, Boston University, Boston, MA, USA), Garry Gold,
M.D., Ph.D. (Radiology, Stanford University, Stanford, CA,
USA), Benjamin Hsu, Ph.D. (GlaxoSmithKline, Research
Triangle Park, NC, USAc), Marissa Lassere, M.B.B.S., Ph.D.,
F.R.A.C.P. (Epidemiology, St George Hospital, Kogarah, Aus-
tralia), Stefan Lohmander, M.D., Ph.D. (Orthopaedics,
University of Lund, Lund, Sweden), Jean-Pierre Raynauld,
M.D. (Rheumatology, University of Montreal and Arthrovision,
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LaRoche Inc, Nutley, NJ, USA), Saara Totterman, M.D.,
Ph.D. (Virtual Scopics, Pittsford, NY, USA), James Witter,
M.D. (FDA, Washington, DC, USA), and Thasia Woodworth,
M.D. (Pﬁzer, Groton, CT, USA). The ﬁndings of this panel
were presented to the participants of the workshop in Be-
thesda, MD, for open discussion. These presentations and dis-
cussions, along with any notable advances that have occurred
since, are summarized in the four reports that follow in this
Supplement.
The ﬁrst of these reports, ‘‘Magnetic Resonance Imaging
(MRI) of Articular Cartilage in Knee Osteoarthritis: Morpho-
logical Assessment’’ by Eckstein et al., provides a
comprehensive review of the current knowledge on semi-
quantitative and quantitative assessment of this important
tissue. The report asserts that cartilage morphology
(volume and thickness) can be quantiﬁed accurately and
precisely using widely available MRI techniques and that
the annual rate of cartilage loss observed in most longitudi-
nal studies (4e6%) exceeds precision error by a factor of
approximately 50%.
In ‘‘MRI of Articular Cartilage in Osteoarthritis: Novel
Pulse Sequences and Compositional/Functional Markers’’,
Gold et al. review some recent innovations in MRI pulse
sequences which promise to improve the contrast and
speed of high-resolution 3D imaging of articular cartilage
morphology. The report also explores novel techniques for
probing the compositional integrity of this key articular
tissue.
As discussed above, although articular cartilage loss is
a cardinal feature of OA, loss of functional integrity of other
articular tissues also plays an important role. Accordingly,
many have proposed modeling OA as a disease of organ
failure, in which dysfunction of one structure is associated
with damage to other structures and collectively these
lead to the pain and functional disability experienced in
OA. In ‘‘MRI of Non-Cartilagenous Structures in the Knee
in Osteoarthritis’’, Conaghan et al. review MRI evaluation
of these other features of OA, particularly abnormalities of
bone, synovium, ligaments and menisci.
In ‘‘MRI Protocols for Whole-Organ Assessment of the
Knee in Osteoarthritis’’, Peterfy et al. discuss the technical
challenges associated with multi-feature imaging of OA in
multi-site, longitudinal studies. The report outlines the key
considerations important for selecting and qualifying imag-
ing sites, designing imaging protocols that will consistently
provide high-quality images across all subjects and sites
Table I
Most important MRI features for evaluating disease severity and
progression in OA of the knee
MRI feature Ranked #1 Ranked #2
Articular cartilage loss 58 1
Osteophytes 36 11
Bone marrow abnormality 35 11
Synovitis 26 17
Meniscal abnormality 17 17
Synovial effusion 16 20
Results are based on a ballot survey of 64 workshop participants.throughout the duration of the study, and for controlling
image quality and managing the image data.
In addition to these discussions, data sets from previous
clinical trials and epidemiological studies of OA were ana-
lyzed with respect to the metrological properties of the mea-
surement methods employed. One of these analyses
examined the internal construct validity of WORMS1,
a whole-organ MRI scoring method for assessing multiple
structural abnormalities in the knee, using data from a clini-
cal trial of OA. The results of this analysis were presented to
the participants of the workshop for discussion. Subsequent
to the workshop, a second clinical epidemiology data set
using WORMS but with a more extensive range of pathol-
ogy was also analyzed in order to strengthen the validity
of the ﬁndings from the ﬁrst analysis. ‘‘Examining
a Whole-Organ Magnetic Resonance Imaging Scoring
System for Osteoarthritis of the Knee using Rasch Analy-
sis’’ by Conaghan et al. summarizes these two analyses
and discusses the challenges associated with combining
measurements from different structures or even from
different regions of the same structure.
In ‘‘Responsiveness, Effect Size, and Smallest Detect-
able Difference of Magnetic Resonance Imaging in Knee
Osteoarthritis’’, Hunter et al. examine the performance of
ﬁve MRI measures for OA of the knee: quantitative cartilage
volume and semi-quantitative cartilage, bone marrow ab-
normality, osteophyte and synovitis/effusion scores based
on reanalysis of data from a prior clinical trial of OA.
Additionally, the workshop also included a poster session
and a ballot survey of the participants’ opinions of which
MRI features were most important for evaluating OA of
the knee. Based on this survey, which included 64 respond-
ing participants (39 rheumatologists, 10 MRI experts, 7
radiologists, 8 other participants), consensus was reached
on a core set of structures to be included in whole-organ
assessment of the knee (Table I). These were, in order of
importance, articular cartilage, osteophytes, subarticular
bone marrow abnormality (sometimes referred to as bone
marrow edema), the synovium, the menisci, and synovial
effusion.
Since this workshop, further advances have been made
in some of the areas that were discussed. However, the
pace of this progress has been slow; limited primarily by
the rate at which the ideas and hypotheses put forth at
the time of the workshop could be validated, since doing
so often requires large, longitudinal studies, which take con-
siderable time and resources. It is hoped that by publishing
these reports, this research will be accelerated and the ﬁeld
will evolve more rapidly toward a deeper understanding of
this enigmatic disease and how best to evaluate its severity,
progression and response to therapy.
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